 |
市场调查报告书
商品编码
1429275
寨卡病毒治疗市场：现况分析与预测（2023-2030）Zika Virus Therapeutics Market: Current Analysis and Forecast (2023-2030) |
||||||
寨卡病毒主要透过家猫叮咬传播。 它在 2015 年和 2016 年因其与受感染母亲所生婴儿的小头畸形和其他出生缺陷相关而受到关注。 寨卡病毒治疗的研究主要集中在疫苗和抗病毒药物的开发。 疫苗开发的目的是创造一种安全有效的疫苗来预防寨卡病毒感染并预防出生缺陷，特别是孕妇。 症状包括发烧、皮疹、关节疼痛和红眼。 其他几个因素，例如寨卡病毒感染数量的增加和水的不断积累，正在推动全球对寨卡病毒治疗的需求。 例如，根据泛美卫生组织的数据，2021年美洲地区共报告了1,430,922例虫媒病毒性疾病病例，其中23,252例（1.6%）为寨卡病例。
由于全球家养猫蚊数量不断增加，寨卡病毒治疗市场预计将稳定成长约5.1%。 2022 年在坦尚尼亚进行的一项研究发现，在测试的总共 333 个盛水容器中，有 201 个（60.4%）至少有家猫幼虫或蛹。 在预测期内，有几个因素推动市场成长，包括蚊媒疾病盛行率上升、对蚊媒疾病的认识不断提高以及医疗保健领域投资的增加。 除此之外，寨卡病毒疗法提高治疗效率的结果是治疗程序更快、准确性更高，这也稳步推动了寨卡病毒疗法市场的发展。
依疫苗类型，市场分为灭活疫苗、次单位疫苗、减毒疫苗等。 2022年，灭活疫苗领域在全球寨卡病毒治疗市场中占据最大份额，因为它可以有效增强人体对病毒的免疫力。 灭活疫苗使用杀死引起疾病的病毒和细菌的疫苗。 这些疫苗会刺激免疫反应，但不会引起疾病本身。 透过将灭活的病原体引入体内，免疫系统学会辨识并对抗特定的病毒和细菌，对未来的感染产生免疫力。 由此可见，2022年灭活疫苗领域将占据较大市场份额。
根据最终用途，市场分为医院、诊所和其他。 到 2022 年，诊所将占据市场的主要份额。 诊所是初级卫生保健机构，患者在这里接受即时诊断、治疗和持续护理。 我们透过提供最先进的医疗设施、专业知识和多学科的患者护理方法，在患者管理中发挥着至关重要的作用。 研究合作和收购的增加正在推动该领域的成长。 因此，诊所类别在预测期内预计将出现更高的复合年增长率。
为了更了解兹卡病毒治疗的市场介绍，市场包括北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、义大利、欧洲其他地区）、亚太地区（中国、日本、印度、亚太其他地区）和世界其他地区。 由于水污染加剧、库蚊数量增加、蚊媒疾病病例增加以及开发有效寨卡病毒治疗方法的投资增加，预计北美将在 2022 年超越目前的市场。 例如，根据美国卫生与公众服务部的数据，截至 2020 年，美国大陆和美国领土上有 200 多种蚊子。 政府机构已启动有关蚊媒疾病的宣传计划，以便为患者提供有效的治疗。 因此，从地区来看，2022年北美将占据较大市场份额。
市场上一些主要的参与者包括 Bharat Biotech、GeneOne Life Science、GSK plc、Hawaii Biotech Inc.、Leidos、INOVIO Pharmaceuticals、LUMOS PHARMA、Cytiva、Takeda Pharmaceutical 和 Cerus Corporation。
目录
第一章市场介绍
- 市场定义
- 主要目标
- 利害关係人
- 限制
第二章研究方法或假设
- 调查过程
- 调查方法
- 受访者简介
第三章市场总结
第 4 章执行摘要
第五章 COVID-19 对兹卡病毒治疗市场的影响
第六章寨卡病毒治疗市场收入，2020-2030
第 7 章按疫苗类型划分的市场洞察
- 灭活□□疫苗
- 次单位疫苗
- 减毒活疫苗
- 其他
第 8 章最终使用者的市场洞察
- 医院
- 诊所
- 其他
第 9 章按地区划分的市场洞察
- 北美
- 美国
- 加拿大
- 其他北美地区
- 欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 其他欧洲地区
- 亚太地区
- 中国
- 日本
- 印度
- 其他亚太地区
- 世界其他地区
第10章寨卡病毒治疗药物市场动态
- 市场驱动因素
- 市场挑战
- 影响分析
第 11 章兹卡病毒治疗市场机会
第十二章寨卡病毒治疗药物市场趋势
第十三章需求方与供给方分析
- 需求方分析
- 供给面分析
第14章价值链分析
第15章竞争场景
- 竞争状况
- 波特五力分析
第十六章公司简介
- Bharat Biotech
- GeneOne Life Science
- GSK plc.
- Hawaii Biotech Inc.
- Leidos
- INOVIO Pharmaceuticals
- LUMOS PHARMA
- Cytiva
- Takeda Pharmaceutical Company Limited
- Cerus Corporation
第十七章免责声明
The Zika virus is primarily transmitted through Aedes mosquito bites. It gained attention in 2015-2016 due to its link to birth defects like microcephaly in babies born to infected mothers. Research on Zika virus therapeutics is primarily focused on developing vaccines and antiviral drugs. Vaccine development aimed to create a safe and effective vaccine to prevent Zika virus infection, especially in pregnant women to protect against birth defects. Symptoms include fever, rash, joint pain, and red eyes. Several other factors, such as the rising cases of zika virus, and constant water accumulation are leading drivers of zika virus therapeutics globally. For instance, according to the Pan American Health Organization, in the Region of the Americas, in 2021, a total of 1,430,922 cases of arboviral disease were reported, of those 23,252 (1.6 %) were Zika cases.
The Zika Virus Therapeutics Market is expected to grow at a steady rate of around 5.1% owing to the rising Aedes mosquito population globally. According to the study performed in 2022 in Tanzania, a total of 333 water-holding containers were inspected and 201 (60.4%) had at least an Aedes larvae or pupae. Several factors, including a rising prevalence of mosquito-borne diseases, increasing awareness regarding mosquito-borne diseases, and increased investments in healthcare departments are driving the growth of the market during the forecast period. Apart from this, accelerated treatment efficiency with zika virus therapeutics has resulted in faster treatment procedures and better accuracy which is also driving this market of zika virus therapeutics at a steady rate.
Based on vaccine type, the market is segmented into inactivated vaccine, subunit vaccine, live-attenuated vaccine, and others. The inactivated vaccine segment held the maximum share in the global market of zika virus therapeutics in 2022 owing to its efficiency in developing immunity in human body against the virus. Inactivated vaccines are created by using a killed version of the virus or bacteria that causes the disease. These vaccines stimulate an immune response without causing the disease itself. By introducing the inactivated pathogen to the body, the immune system learns to recognize and fight the specific virus or bacteria, providing immunity against future infections. Thus, the inactivated vaccine segment held a significant share of the market in 2022.
Based on end use, the market is segmented into hospitals, clinics, and others. The clinics held a significant share of the market in 2022. Clinics serve as primary healthcare institutions where patients receive an immediate diagnosis, treatment, and ongoing care. They play a pivotal role in the management of patients by providing state-of-the-art medical facilities, specialized expertise, and a multidisciplinary approach to patient care. Rising collaborations and acquisitions are boosting this segment's growth. Hence, the clinics category is expected to witness higher CAGR during the forecast period.
For a better understanding of the market adoption of zika virus therapeutics, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the increasing water pollution, rising Aedes mosquito population, increasing cases of mosquito-borne diseases, and rising number of investments in developing effective zika virus therapeutics. For example, in 2020, according to U.S. Department of Health & Human Services, over 200 types of mosquitoes live in the continental U.S. and U.S. territories; of these 200, about 12 types spread germs that can make people sick. Government organizations are initiating mosquito-borne diseases awareness programs to provide efficient care to patients. Thus, amongst regions, North America held a significant share of the market in 2022.
Some of the major players operating in the market include Bharat Biotech; GeneOne Life Science; GSK plc.; Hawaii Biotech Inc.; Leidos; INOVIO Pharmaceuticals; LUMOS PHARMA; Cytiva; Takeda Pharmaceutical Company Limited; Cerus Corporation.
TABLE OF CONTENTS
1 MARKET INTRODUCTION
- 1.1. Market Definitions
- 1.2. Main Objective
- 1.3. Stakeholders
- 1.4. Limitation
2 RESEARCH METHODOLOGY OR ASSUMPTION
- 2.1. Research Process of the Zika Virus Therapeutics Market
- 2.2. Research Methodology of the Zika Virus Therapeutics Market
- 2.3. Respondent Profile
3 MARKET SYNOPSIS
4 EXECUTIVE SUMMARY
5 IMPACT OF COVID-19 ON THE ZIKA VIRUS THERAPEUTICS MARKET
6 ZIKA VIRUS THERAPEUTICS MARKET REVENUE (USD BN), 2020-2030F
7 MARKET INSIGHTS BY VACCINE TYPE
- 7.1. Inactivated Vaccine
- 7.2. Subunit Vaccine
- 7.3. Live-attenuated Vaccine
- 7.4. Others
8 MARKET INSIGHTS BY END-USER
- 8.1. Hospitals
- 8.2. Clinics
- 8.3. Others
9 MARKET INSIGHTS BY REGION
- 9.1. North America
- 9.1.1. U.S.
- 9.1.2. Canada
- 9.1.3. Rest of North America
- 9.2. Europe
- 9.2.1. Germany
- 9.2.2. U.K.
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Rest of Europe
- 9.3. Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Rest of Asia-Pacific
- 9.4. Rest of World
10 ZIKA VIRUS THERAPEUTICS MARKET DYNAMICS
- 10.1. Market Drivers
- 10.2. Market Challenges
- 10.3. Impact Analysis
11 ZIKA VIRUS THERAPEUTICS MARKET OPPORTUNITIES
12 ZIKA VIRUS THERAPEUTICS MARKET TRENDS
13 DEMAND AND SUPPLY-SIDE ANALYSIS
- 13.1. Demand Side Analysis
- 13.2. Supply Side Analysis
14 VALUE CHAIN ANALYSIS
15 COMPETITIVE SCENARIO
- 15.1. Competitive Landscape
- 15.1.1. Porters Fiver Forces Analysis
16 COMPANY PROFILED
- 16.1. Bharat Biotech
- 16.2. GeneOne Life Science
- 16.3. GSK plc.
- 16.4. Hawaii Biotech Inc.
- 16.5. Leidos
- 16.6. INOVIO Pharmaceuticals
- 16.7. LUMOS PHARMA
- 16.8. Cytiva
- 16.9. Takeda Pharmaceutical Company Limited
- 16.10. Cerus Corporation
